Sharing in the 5 billion dollar stateside bone marrow transplant market: advanced commercial stem ce

Pluristem Life Systems, Inc. is a cell therapy company dedicated to the commercialization of stem cell therapy products for the treatment of severe blood disorders. Pluristem is discovering and developing cell-based theraputics utilizing only adult stem cells expanded in a proprietary bio-reactor that mimics different naturlly-occurring physiological environments.

[ClickPress, Thu Jul 13 2006] An advanced line of stem cell grafts proven to increas the effectiveness of stem cells by 2-4 times in a pre-clinical animal model study are the first commercial stem cell therapy products planned for launch in the U.S. by Pluristem Life Systems, Inc. (OTCBB:PLRS). Additional animal studies and human clinical trials are expected to prove as equally successful. These new products developed from umbilical cord blood and placenta will effectively do away with the current bone marrow transplant search-match process and can dramatically change the way bone marrow transplants are conducted in the future. When offered to the medical community in the U.S., Pluristem should be positioned to capture a significant share of the 5 billion dollar commercial bone marrow transplant market making the Company a major player in the industry.


About Pluristem

Pluristem Life Systems, Inc. is a cell therapy company dedicated to the commercialization of stem cell therapy products for the treatment of severe blood disorders. Pluristem is discovering and developing cell-based theraputics utilizing only adult stem cells expanded in a proprietary bio-reactor that mimics different naturlly-occurring physiological environments.


Safe Harbor Statement

This news release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: Pluristem has an advanced line of stem cell grafts proven to increas the effectiveness of stem cells by 2-4 times in a pre-clinical animal model study, these products are the first commercial stem cell therapy products planned for launch in the U.S. by Pluristem, if additional animal studies and human clinical trials prove as equally successful, these new products developed from umbilical cord blood and placenta will effectively do away with the current bone marrow transplant search-match process and dramatically change the way bone marrow transplants are conducted in the future, when offered to the medical community in the U.S. Pluristem should be positioned to capture a significant share of the 5 billion dollar commercial bone marrow transplant market making the Company a major player in the industry. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be apprved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

www.pluristem.com



Media Contact:

Jerry Jennings
Emerson Gerard Associates, Inc.
West Palm Beach, FL
561-881-7318
mediareply@emersongerard.com

###

This press release was issued through GroupWeb EmailWire.Com.